Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dear wiseacre mention one otc stock without debt. You think youre the smartest here with your opnion about debt. Well go ahead mention one. In otc land all companies have debts, revo including.
I see big buys. 20s up
Did i see a buy?? Thats long ago!
We only know one thing...... "We" is that you and your bowl of glass where youre looking in.... Cant understand spending your time here...
Doesnt matter now, i have enough shares now, locked at 0,33. Waiting for news now. Good luck!
My dutch brooker places my buy-order at an american brooker. Just got the last 30 k at 0,028!
Called my dutch brooker: otc market is incourant; the rest of my order, 30 k with limit 0,0285 is still there but not filled. Strange...
Thanx!!!! Good luck!
Sharky can you please show l2. Order in 40 k limit 0,0285. Got 10 k but not the rest? Ask is 0,0283
You completely missed the boat here, maybe a 0,0250 dumper can safe you. Do your dd and watch next week!
50% down? Keep on dreaming!!
Where Generex Biotechnology Corporation (OTCMKTS:GNBT) is Expected to Find Support?
? 0
By James Elliot on November 26, 2014 Micro Cap Insider, Small Caps
Generex Biotechnology Corporation (OTCMKTS:GNBT) is trading strong just under its base at the $0.02 level. The stock saw a big spike in October after the Company Clarified Utility of Antigen Express Technology for Potential Ebola Vaccine.
Generex Biotechnology Corporation (OTCMKTS:GNBT) is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device.
Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.
On October 7 GNBT responded to a recent article posted to the Seeking Alpha website regarding the need for an Ebola vaccine and the importance of providing funding for small companies with technologies applicable to such an endeavor. Generex is the parent company of Antigen Express, Inc. which focuses on the development of synthetic peptide vaccines for significant unmet medical needs.
We Have a MASSIVE Stock Pick Coming ASAP. Only a Crazy Person would Miss this!
Antigen Express has previously published its work on the development of a vaccine for potentially pandemic viruses such as the H5N1 (avian flu) and H1N1 (swine flu) influenza strains. The advantage of the technology is that it entails entirely synthetic production methods, which are rapid, cost effective, and flexible. The vaccine is produced using a small fragment derived from a target protein modified to ensure activation of CD4+ T helper cells. This cell type is critical in the generation of an effective immune response to a novel agent.
Antigen Express remains committed to its belief that a synthetic vaccine technology is a crucial component of a government’s preparedness arsenal for outbreaks of agents with high pathogenicity such as Ebola or the emergence of other potentially pandemic agents. Toward that goal, the Company is exploring opportunities for application of Antigen Express technology in the development of an effective Ebola vaccine.
There are currently a number of vaccines in development for Ebola, though none have yet been approved. Some of these require repeated administration to obtain some level of protection in animal models, in contrast to the influenza virus vaccines. Early efforts to generate a protective antibody response against Ebola clearly showed the importance of CD4+ T cells. The need for continued or repeated immunization is a good indication of the need for a stronger CD4+ T cell response, as specific activation of this cell type is associated both with immunological memory as well as a robust early response to immunization.
Conclusion: GNBT continues to trade strong just under the $0.02 level. The stock has had several run ups topping out a nickel over the past 2 years with the trading range being $0.01 to $0.05. Currently trading at a $16.3 million market valuation the Company has a very strong cash position of $4 million in the treasury. Do not be fooled when u see GNBT illiquid at $0.02, this is a stock to watch!
Thanks, nice thanksgiving; i didnt want to take the risk for a mucher higher pps so i bouhgt at 0215.
Sharky can you show 1 x l2 again. Want to buy for a friend. Thanx
Lol! Good you are back. Youre doing a good dd everytime!
Hey smguru back here. Missed you a while!
I understand you called him, no more information than posted? Dissapoinment, a change to get more info
Got them!
Thanx, try at 135, maybe a dumper.
Hello sharky, can you please post l2 snapshot. I want to buy another 90 k. Thanx
Nice close! No dude sarcasm and i know everything better than you today!
Schools out iceinvest; go and play else for a while, man are you childisch!
I have a dutch brooker, dont know which brooker they use in US. Wont sell below 25 cent. Thanx for reaction. Good luck!
This cant stay at these levels very long. Shorted by group or institute will find buyers soon!
I locked my 310 k shares at 25 cents. Cant see them in L2
Hows italy today, expecting good news?
Doesnt matter if i looked like you i would not do it
Fools?? I am sure you didnt look in the mirror.
Yes, about 1,2 milion at 17
Thats one of the reasons no one is buying. Put a bid and you get filed. The more you bid the sooner you get your shares from the shorter. He can do this without risk. After the bell he has them back.
My opinion is that everybody sees the dayly t trades but nobody knows whos behind this. Its meant to drive the price down. People go short and get shares after the bell at the lowest price of the day.
Did you get that answer from the sec?Today more than 4 million sold. Most at 17/18. Watch it : t trade after hours at 15. This is the daily pattern: a few cents below the most traded sell price. Who is behind this?
Maybe youre right based on no cure no pay!
If they see by looking at a case that there is no change to win they wont start a case. Thats bad for their name
Good work maronti, thanks!
Look at the Os/float. No change so no new shares
Is that really you on the picture mr foot! If i looked like you i would place no picture but now i understand your level of posts here
Even bigger nonsense. First you say note holders are selling, and now they have the shares bit cant sell them. What do i miss??!
Difficult for me maronti, i am from holland and my englisch is not good enough to tell them whats going wrong
As usual you are totally wrong. No change in number of shares; t trades since weeks, so no noteholders!